736 , Shakti Khund III , New Delhi

Global Biosimilars Market By Product Type (Insulin, Erythropoietin, Others), By Application (Oncology, Blood Disorders, Others), By End User (Research, Hospitals & clinics, Others), By Region–Forecast & Opportunities to 2026

Report Description

The biosimilars market valued USD 9.0 billion in 2019. Biosimilars market is projected to grow at a CAGR of 19.2% from 2020 to 2026.

Covid19 has impacted the Pharmaceuticals market in a way that everyone is talking only about this virus. The pharmaceuticals industries are majorly focusing on developing either a treatment or a vaccine for this virus. COVID-19 doesn’t impacted biosimilars market negatively. There is no decline seen in this market due to COVID-19. This market will continue to grow as before.


Biosimilars can be defined as the drugs which are highly similar to approved biologic drugs. They have similar medical properties in terms of safety and potency to the original products. These products have high prevalence of chronic disease such as cancer, growth hormone deficiency, diabetics and anemia.

Market Dynamics (Drivers/Opportunities):

Many biological drugs are moving towards patent cliff. In 1997 the U.S. Food and drug association had approved Rituxan, a monoclonal antibody biologics. This is a very vital driving factor of biosimilars market.

In clinical trials biosimilars have positive outcomes and they are cost efficient as compared to other patented biologics. This drives the market and give biosimilars market a boost. As an example the results of Amgen stated in its phase 3 clinical study of ABP 980 as compared with trastuzumab, a monoclonal antibody which was approved for early metastatic gastric cancer.

Biosimilars drug is a cost saving alternatives which is why it is experiencing a huge market growth. Many companies such as Teva Pharmaceutical Ltd., Biocon and Mylan N.V. etc are focusing much more than usual on developing and producing a biosimilars. This factor is expected to drive biosimilars market to witness immense growth in near future.

The number cancer cases are growing across the globe. In 2012 there were total 14 million cases of cancer and approx 8 million deaths due to cancer took place worldwide. In 2016 there were 29 million diabetes cases in U.S. There is a high demand for biosimilars in order to treat such diseases thus leading to huge opportunities and boost in biosimilars market.

Market Insights, by Product Type

On the basis of product the biosimilars market is segmented into insulin, monoclonal antibodies, granulocyte colony-stimulating factor, erythropoietin, recombinant gycosylated proteins, recombinant non-gycosylated proteins, etanercept, follitropin, teriparatide, interferon, enoxaparin sodium, glucagon and calcitonin. Monoclonal has accounted for largest market share in 2019.

Recombinant gycosylated proteins segment is expected to grow at a highest CAGR during the forecast period. The major driving factors for this industry are patent cliff, growing number of chronic disease cases and number increasing product launches and approvals.


Market Insights, by Applications

Based on the application, the biosimilars market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic & autoimmune disorders and others. The oncology segment had accounted for maximum market share by revenue in 2019. World health organization (WHO) has declared cancer as the second leading cause of death around the world. In 2015 8.8 million deaths occurred due to cancer. Out of 8.8 million deaths around 70% people died are from lower or middle income country, who can’t afford the cost of treatment. Hence there is an increased demand of low cost and highly effective therapeutic drugs.

The blood disorder segment is estimated to register growth at higher CAGR during the forecast period. The number of blood disorder cases is growing immensely throughout the world and the adoption of biosimilars are also increasing in the treatment of blood disorder cases as biosimilars are most efficient and low cost solution.

Market Insights, by End-Users

Based on the end users the market is divided into research, hospitals and clinics and others. The healthcare and clinics segment is estimated to register growth at highest CAGR during the forecast period. Biosimilars provide low cost and efficient treatments for many diseases such as cancer, blood disorder and diabetics etc. Biosimilars are affordable by low and middle income countries. Such countries use biosimilars in clinics and hospitals at large scale to treat patient.

Regional Insights

Based on region, Europe accounted for largest market share in 2019. The increment of chronic diseases was the major driving factor in this region. To treat such diseases the most efficient and low cost solution was the use of biosimilars. This has maximized the market size of biosimilars in the Europe region.

North America is expected to register growth at highest CAGR during the forecast period. The manufacturers are putting great efforts in order to tap great opportunities in this region. The presence of significant manufacturers and state-of-art facilities for the production of biosimilars market are major driver of market.

Key Companies & Market Share Insights

The key market players in this sector are Teva Pharmaceutical Ltd., Biocon and Mylan N.V., Agmen, Pfizer, Sandoz International, Dr. Reddy’s Laboratories, Celltrion, Samsung Biologics, Eli Lily and company, Hospira Inc., Cipla Ltd., Actavis Inc., Biogen and Stada Arzneimittel Ag.

Sandoz is the leading company in 2019 and it is expected to maintain its dominance over the biosimilars market. All the key players in these industries are focusing on producing most efficient and low cost biosimilars to strengthen their market and presence profitability.

Segments Covered in the Report

This report forecasts The Global Biosimilars Market, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2026. For the purpose of this study, Our Company has segmented the global Automotive Brake System market report on the basis of product type, application, and end-user.

Biosimilars Market Size & Forecast (2017-2026)

  1. Research Framework
    • Market Definition and Product Overview
    • Market Segmentation
  2. Research Methodology
    • Qualitative Research
      • Primary & Secondary Sources
    • Quantitative Research
      • Primary & Secondary Sources
    • Breakdown of Primary Research Respondents,By Region
      • Secondary Research
      • Primary Research
    • Breakdown of Primary Research Respondents,By Industry Participants
      • Market Size Estimation
      • Assumption for the Study
      • Market Breakdown & Data Triangulation
  3. Executive Summary
    • Market Snapshot
  4. Industry Insights
    • Industry ecosystem analysis
      • ValueChain Analysis
    • Industry impact and forces
      • Growth Drivers
      • Challenges &Restraints
      • Opportunities
    • Disruptive Technological Analysis
    • Regulatory framework
      • North America
      • Europe
      • Asia Pacific
      • Middle East & Africa
      • South America
    • Growth potential analysis, 2019
    • Porter’s Five forces analysis
    • Pricing Analysis
      • North America
      • Europe
      • Asia Pacific
      • Middle East & Africa
      • South America
  1. COVID – Impact Analysis
    • North America
    • Europe
    • Asia Pacific
    • Middle East & Africa
    • South America
  2. Biosimilars Market,By Product Type, Market Size & Forecast To 2026

(USD Million 2017,2018, 2019, 2020, 2021-e-2026-p)

  • Introduction
  • Insulin
  • Monoclonal Antibodies Granulocyte Colony-Stimulating Factor
  • Erythropoietin
  • Recombinant Non-Gycosylated Proteins
  • Recombinant Gycosylated Proteins
  • Etanercept
  • Follitropin
  • Teriparatide
  • Interferon
  • Enoxaparin Sodium
  • Glucagon
  1. Biosimilars Market,By Application, Market Size & Forecast To 2026

(USD Million 2017,2018, 2019, 2020, 2021-e-2026-p)

  • Introduction
  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic & Autoimmune Disorders
  • Others
  1. Biosimilars Market,By End User, Market Size & Forecast To 2026

(USD Million 2017,2018, 2019, 2020, 2021-e-2026-p)

  • Introduction
  • Research
  • Hospitals & clinics
  • Others
  1. Biosimilars Market,By Region, Market Size & Forecast To 2026

(USD Million 2017,2018, 2019, 2020, 2021-e-2026-p)

  • Introduction
  • North America Market Size & Forecast To 2026
    • Market Overview
    • COVID-19 Impact
    • By Product Type
    • By Application
    • By End-User
    • By Country
      • USA
        • By End-User
      • Canada
      • Mexico
    • South America Market Size & Forecast To 2026
      • Market Overview
      • COVID-19 Impact
      • By Product Type
      • By Application
      • By End-User
      • By Country
        • Brazil
          • By End-User
        • Argentina
        • Chile
        • Rest of South America
      • Europe Market Size & Forecast To 2026
        • Market Overview
        • COVID-19 Impact
        • By Product Type
        • By Application
        • By End-User
        • By Country
          • UK
            • By End-User
          • Germany
          • France
          • Italy
          • Rest of Europe
        • APAC Market Size & Forecast To 2026
          • Market Overview
          • COVID-19 Impact
          • By Product Type
          • By Application
          • By End-User
          • By Country
            • China
              • By End-User
            • India
            • Japan
            • South Korea
            • Australia
            • Rest of APAC
          • Middle East & Africa Market Size & Forecast To 2026
            • Market Overview
            • COVID-19 Impact
            • By Product Type
            • By Application
            • By End-User
            • By Country
              • Saudi Arabia
                • By End-User
              • UAE
              • Qatar
              • Kuwait
              • South Africa
              • Rest of Middle East & Africa
  1. Competitive Landscaping
    • Competitive Benchmarking
      • Market Share Analysis, 2019
      • Global Presence and Growth Strategies
        • Mergers & Acquisitions
        • New Product Launches
        • Investments Trends
        • R&D Initiatives
  1. Company Profile
    • Sandoz International
      • Company Overview
      • Financial Overview
      • Product Portfolio
      • Recent Developments
      • SWOT Analysis
      • Strategic Outlook
    • Teva Pharmaceutical Ltd.
    • Biocon
    • Mylan N.V.
    • Agmen
    • Pfizer
    • Reddy’s Laboratories
    • Celltrion
    • Samsung Biologics
    • Eli Lily and company
    • Hospira Inc.
    • Cipla Ltd.
    • Actavis Inc.
    • Biogen
    • Stada Arzneimittel Ag.
  2. Appendix
    • Interrelated Market



Q Research Methodology

1.1     Research Methodology

The process of market research at PAN Market Consulting is very intuitive being iterative in nature and usually follows the path where Information gathered from secondary research is used to build data models, which are than validated from primary participants. Then same cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new information type is again incorporated into data model. The process continues till desired level of information is not generated.

To calculate the market size, the report considers the revenue generated from the sales of the product/services. The revenue generated from the sales of product/services has been calculated through primary and secondary research. The report also analyses the key players operating in the market at the global level which are identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes product segmentation determined using secondary sources and verified through primary sources.

1.2     Secondary Research

The secondary research source that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • Internal and external proprietary databases, relevant patent and regulatory databases
  • National government documents, statistical databases and market reports
  • News articles, press releases and web-casts specific to the companies operating in the market

The source for secondary research includes but is not limited to Factiva, Hoovers and Statista


1.3     Primary Research

We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following end users:

  • It provides first-hand information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
  • Helps in validating and strengthening the secondary research findings
  • Further develops the analysis team’s expertise and market understanding
  • Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/ product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
  • Key opinion leaders specializing in different areas corresponding to different industry end users

1.4     Models

Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data products to produce estimates:

  • Demographic data: Population split by segment
  • Macro-economic indicators: GDP, etc.
  • Industry indicators: Expenditure, product stage & infrastructure, sector growth and facilities.

Data is then cross checked by the expert panel.

1.4.1 Company Share Analysis Model

Company share analysis is used to derive the size of global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps:


1.4.2 Revenue Based Modeling

Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach whereas it acts as starting point for top-down approach.


Please share your details to receive a sample copy of the report

Single User : $3750
Multi User : $6100
Buy Now


Why Choose Us

  • 24*7 Post Sales Support
  • Speak to Analyst for Presentations
  • 15% Free Customization
  • Global, Regional & Country level reports
  • Special Discounts for Startups & Educational Institutions

Questions ?

  • What is 15% Free Customization?
  • What is Report Subscription?
  • What is the Delivery Time of the Report?

What You Get

Data Excel Sheets

Report in PDF

Report Subscription

Analyst Support

What's Included

Market Intelligence

Competitive Intelligence

Opportunities and Challenges

Strategic Recommendations